Blog
Supporting You In Dealing With Trauma Why Trauma-Informed Lawyering is Crucial
Eurydice Cote
In September 2020, the first NHS prescription for cannabis medicine was issued to Billy Caldwell. This brought hope to him, his family and so many others that this medicine would become readily available to those patients who so desperately need it.
Guest author Edward Henry QC, of Mountford Chambers, considers the ongoing issues regarding access to medicinal cannabis, specifically relating to the treatment of children, in the United Kingdom (UK).
As the regulatory landscape around cannabis in the UK evolves, investors are looking toward cannabis companies as a socially conscious investment, but in the UK, the drug is a controlled substance, as such, careful considerations need to be borne in mind. Here, Shannett Thompson explains the legal landscape around cannabis and its implications for investing in cannabis as a UK national.
In September 2020 the FCA published a statement regarding the listing of cannabis-related businesses (CRBs) in the UK. Since then several CRBs have been admitted to the London Stock Exchange (LSE) and appetite for investments in the medicinal cannabis industry continues to grow.
Headlines such as “Spain becomes cannabis hub as criminals fill tourism void” (The Guardian 9 October 2020) serve to remind us of the endemic demand for marijuana, the resultant profits to be made and enforcement agencies’ inability to control Europe’s illegal trade run by drug mafias. By contrast, Canada, on 17 October 2018 and following the example of Uruguay, elected to legalise adult personal possession, sharing and cultivation of recreational cannabis.
Legal Notices
|
Privacy Notice
|
Fraud Warning
|
Modern Slavery Statement
|
Complaints
|
Website Terms
|
Cookie Policy
|
Accessibility
|
Site Map
© Kingsley Napley LLP. All rights reserved. Authorised and regulated by the Solicitors Regulation Authority, registration number 500046.
Skip to content Home About Us Insights Services Contact Accessibility